Nasus Pharma (NSRX) vs ProMIS Neurosciences (PMN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Nasus Pharma (NSRX) has outperformed ProMIS Neurosciences (PMN) over the past year, losing 68.4% versus a loss of 69.9%. ProMIS Neurosciences is the larger company by market cap ($28.4 million vs $26.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NSRX | PMN |
|---|---|---|
| Share price | $2.29 | $3.16 |
| Market cap | $26.82M | $28.43M |
| 1-day change | -10.20% | -1.56% |
| YTD return | -74.97% | -53.73% |
| 1-year return | -68.41% | -69.90% |
| 5-year return | — | -98.24% |
| EPS (TTM) | $-1.20 | $-6.50 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.24B | — |
| Net income (latest FY) | $-5.86M | $-39.72M |
| Operating margin | -0.40% | — |
| Net margin | -0.47% | — |
| 52-week high | $9.50 | $27.40 |
| 52-week low | $1.98 | $2.78 |
| Distance from 52-week high | -75.89% | -88.47% |
| Analyst consensus | buy | none |
| Avg. price target upside | +758.95% | +1248.42% |
| Average volume | 16.80K | 164.88K |
| Shares outstanding | 11.71M | 9.00M |
| Employees | 7 | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Nasus Pharma
NSRX stock →Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About ProMIS Neurosciences
PMN stock →ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
NSRX vs PMN FAQ
Which is bigger, Nasus Pharma or ProMIS Neurosciences?
ProMIS Neurosciences (PMN) is larger, with a market capitalization of $28.43M compared with $26.82M for Nasus Pharma (NSRX).
Which stock has performed better over the past year, NSRX or PMN?
NSRX returned -68.41% over the past 12 months, compared with -69.90% for PMN (price return, excluding dividends). Past performance does not predict future results.
Are Nasus Pharma and ProMIS Neurosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.